Lucid Announces Closing of $300 Million Investment from Uber
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Canaccord Genuity on Lucid Diagnostics Inc (LUCD): 'we believe the stock does not reflect the company's long-term growth potential'
September 5, 2025 5:16 AM EDT(Updated - September 5, 2025 5:32 AM EDT)
Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD)
The analyst comments "We reiterate our BUY rating on Lucid Diagnostics (LUCD) shares and maintain our price target at $3. Intraday on Thursday, September 4, MolDX-participating Medicare Administrative Contractors (MACs) convened a MolDX Contractor Advisory Committee (CAC)... More
